CAMBRIDGE, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the 32 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014 at 3:00 p.m. (PT) at the Westin St. Francis Hotel in San Francisco.
A live webcast of the presentation can be accessed by visiting the Investors section of Merrimack's website at investors.merrimackpharma.com. A replay of the webcast will be archived on Merrimack's website for two weeks following the presentation.
About MerrimackMerrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development. For more information, please visit Merrimack's website at www.merrimackpharma.com . Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
CONTACT: Investor Contact: Geoffrey Grande, CFA Merrimack 617-441-7602 email@example.com Media Contact: Dana Robie Merrimack 617-441-7408 firstname.lastname@example.org